These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

882 related articles for article (PubMed ID: 10637445)

  • 21. Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum.
    Kobayashi S; Ogren SO; Hoffer BJ; Olson L
    Exp Neurol; 1998 Dec; 154(2):302-14. PubMed ID: 9878169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons.
    Bowenkamp KE; Hoffman AF; Gerhardt GA; Henry MA; Biddle PT; Hoffer BJ; Granholm AC
    J Comp Neurol; 1995 May; 355(4):479-89. PubMed ID: 7636027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.
    Brizard M; Carcenac C; Bemelmans AP; Feuerstein C; Mallet J; Savasta M
    Neurobiol Dis; 2006 Jan; 21(1):90-101. PubMed ID: 16084732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
    Bowenkamp KE; Lapchak PA; Hoffer BJ; Miller PJ; Bickford PC
    Exp Neurol; 1997 May; 145(1):104-17. PubMed ID: 9184114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
    Connor B
    Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model.
    Yang X; Mertens B; Lehtonen E; Vercammen L; Bockstael O; Chtarto A; Levivier M; Brotchi J; Michotte Y; Baekelandt V; Sarre S; Tenenbaum L
    J Gene Med; 2009 Oct; 11(10):899-912. PubMed ID: 19639608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats.
    Lu X; Hagg T
    J Comp Neurol; 1997 Nov; 388(3):484-94. PubMed ID: 9368855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of GDNF in neuronal protection against 6-OHDA-induced parkinsonism following intracerebral transplantation of fetal kidney tissues in adult rats.
    Borlongan CV; Zhou FC; Hayashi T; Su TP; Hoffer BJ; Wang Y
    Neurobiol Dis; 2001 Aug; 8(4):636-46. PubMed ID: 11493028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin.
    Rosenblad C; Grønborg M; Hansen C; Blom N; Meyer M; Johansen J; Dagø L; Kirik D; Patel UA; Lundberg C; Trono D; Björklund A; Johansen TE
    Mol Cell Neurosci; 2000 Feb; 15(2):199-214. PubMed ID: 10673327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor.
    Ding YM; Jaumotte JD; Signore AP; Zigmond MJ
    J Neurochem; 2004 May; 89(3):776-87. PubMed ID: 15086533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
    Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
    Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Marked dopaminergic cell loss subsequent to developmental, intranigral expression of glial cell line-derived neurotrophic factor.
    Chun HS; Yoo MS; DeGiorgio LA; Volpe BT; Peng D; Baker H; Peng C; Son JH
    Exp Neurol; 2002 Feb; 173(2):235-44. PubMed ID: 11822887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
    Lapchak PA; Araujo DM; Hilt DC; Sheng J; Jiao S
    Brain Res; 1997 Nov; 777(1-2):153-60. PubMed ID: 9449424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor.
    Georgievska B; Carlsson T; Lacar B; Winkler C; Kirik D
    Eur J Neurosci; 2004 Dec; 20(11):3121-30. PubMed ID: 15579166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
    Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
    Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
    Ericson C; Georgievska B; Lundberg C
    Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
    Andereggen L; Meyer M; Guzman R; Ducray AD; Widmer HR
    Brain Res; 2009 Jun; 1276():39-49. PubMed ID: 19389387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of GDNF on nigrostriatal dopaminergic function in response to a two-pulse K(+) stimulation.
    Xu K; Dluzen DE
    Exp Neurol; 2000 Dec; 166(2):450-7. PubMed ID: 11085910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative analyses of GFRalpha-1 and GFRalpha-2 mRNAs and tyrosine hydroxylase protein in the nigrostriatal system reveal bilateral compensatory changes following unilateral 6-OHDA lesions in the rat.
    Kozlowski DA; Miljan EA; Bremer EG; Harrod CG; Gerin C; Connor B; George D; Larson B; Bohn MC
    Brain Res; 2004 Aug; 1016(2):170-81. PubMed ID: 15246853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.